Aggressive NK-Cell Leukemia
NCI Definition: A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen. 
There is 1 clinical trial for aggressive NK-cell leukemia, of which 1 is open and 0 are completed or closed. Of the trial that contains aggressive NK-cell leukemia as an inclusion criterion, 1 is early phase 1 (1 open).
Allogeneic hematopoietic stem cell transplantation, calaspargase pegol, and dexamethasone are the most common interventions in aggressive NK-cell leukemia clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.